Form S-8 Coherus Oncology, Inc.
As filed with the Securities and Exchange Commission on August 5, 2026 Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Coherus Oncology, Inc.
(Exact name of registrant as specified in its charter)
Delaware | | 27-3615821 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification Number) |
333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065
(650) 649-3530
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Coherus Oncology, Inc. Amended and Restated 2014 Equity Incentive Award Plan
(Full Title of the Plan)
Dennis M. Lanfear
President and Chief Executive Officer
Coherus Oncology, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065
(650) 649-3530
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Benjamin A. Potter, Esq. Drew Capurro, Esq. Latham & Watkins LLP 801 Jefferson Avenue, Suite 300 Redwood City, CA 94063 (650) 328-4600 |
| Bryan McMichael Chief Financial Officer 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 (650) 649-3530 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ |
| Accelerated filer ☒ |
Non-accelerated filer ☐ | | Smaller reporting company ☒ |
| | Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 7,700,000 shares of common stock of Coherus Oncology, Inc. (the “Registrant”), par value $0.0001 per share, reserved for issuance under the Registrant’s Amended and Restated 2014 Equity Incentive Award Plan (together with previous versions of such plan, and as may be further amended from time to time, the “2014 Plan”), as approved by the Registrant’s shareholders on May 27, 2026 for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-200593, 333-203356, 333-209936, 333-216679, 333-222700, 333-229480, 333-236068, 333-251876, 333-262134, 333-269291, 333-278314 and 333-281394) are effective.
INCORPORATION BY REFERENCE OF CONTENTS OF
REGISTRATION STATEMENTS ON FORM S-8
Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission on November 25, 2014 (File No. 333-200593), April 10, 2015 (File No. 333-203356), March 4, 2016 (File No. 333-209936), March 14, 2017 (File No. 333-216679), January 25, 2018 (File No. 333-222700), February 1, 2019 (File No. 333-229480), January 24, 2020 (File No. 333-236068), January 4, 2021 (File No. 333-251876), January 13, 2022 (File No. 333-262134), January 18, 2023 (File No. 333-269291), March 28, 2024 (File No. 333-278314) and August 8, 2024 (File No. 333-281394) are incorporated by reference herein.
INDEX TO EXHIBITS
| | Incorporated by Reference | | ||
Exhibit | Description | Form | Exhibit | Date Filed | Filed |
| | | | | |
3.1 | Amended and Restated Certificate of Incorporation of the Registrant. | 8-K | 3.1 | 11/13/2014 | |
| | | | | |
3.2 | 8-K | 3.1 | 5/30/2025 | | |
| | | | | |
3.3 | 8-K | 3.1 | 11/18/2020 | | |
| | | | | |
4.1 | S-1/A | 4.2 | 10/24/2014 | | |
| | | | | |
5.1 | | | | X | |
| | | | | |
23.1 | | | | X | |
| | | | | |
23.2 | Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm. | | | | X |
| | | | | |
24.1 | Power of Attorney (included in the signature page to this registration statement). | | | | X |
| | | | | |
99.1(a)# | Coherus Oncology, Inc. Amended and Restated 2014 Equity Incentive Award Plan. | 10-Q | 10.2 | 8/07/2025 | |
| | | | | |
99.1(b)# | Amendment to Coherus Oncology, Inc. Amended and Restated 2014 Equity Incentive Award Plan. | | | | X |
| | | | | |
99.1(c)# | S-1/A | 10.11(b) | 11/4/2014 | | |
| | | | | |
99.1(d)# | S-1/A | 10.11(c) | 11/4/2014 | | |
| | | | | |
99.1(e)# | S-1/A | 10.11(d) | 11/4/2014 | | |
| | | | | |
107 | | | | X | |
# Indicates management contract or compensatory plan.
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Redwood City, California, on August 5, 2026.
| COHERUS ONCOLOGY, INC. | |
| By: | /s/ Dennis M. Lanfear |
| | Dennis M. Lanfear |
| | President and Chief Executive Officer |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Dennis M. Lanfear and Bryan McMichael, and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file this Registration Statement, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
Signature | Title | Date |
/s/ Dennis M. Lanfear | Chairman, President and Chief Executive Officer (Principal Executive Officer) | August 5, 2026 |
Dennis M. Lanfear | ||
| | |
/s/ Bryan McMichael | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | August 5, 2026 |
Bryan McMichael | ||
| | |
/s/ Lee N. Newcomer | Director | August 5, 2026 |
Lee N. Newcomer | ||
| | |
/s/ Ali J. Satvat | Director | August 5, 2026 |
Ali J. Satvat | ||
| | |
/s/ Mats Wahlström | Director | August 5, 2026 |
Mats Wahlström | ||
| | |
/s/ Charles Newton | Director | August 5, 2026 |
Charles Newton | ||
| | |
/s/ Michael Ryan | Director | August 5, 2026 |
Michael Ryan | ||
| | |
/s/ Jill O’Donnell-Tormey | Director | August 5, 2026 |
Jill O’Donnell-Tormey | ||
| | |
/s/ Rita Karachun | Director | August 5, 2026 |
Rita Karachun |
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
- /C O R R E C T I O N -- National Law Enforcement Officer Hall of Fame/
- From Gaming to Fintech: Where Digital Platforms Are Finding New Revenue
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share